Supply Remdesivir C...

Supply Remdesivir Competitive price on hot selling
Supply Remdesivir Competitive price on hot selling
Supply Remdesivir Competitive price on hot selling
Supply Remdesivir Competitive price on hot selling

Supply Remdesivir Competitive price on hot selling

Min.Order / FOB Price:Get Latest Price

1 Kilogram

FOB Price:USD 11500.0000 -12500.0000

  • Min.Order :1 Kilogram
  • Purity: 99%
  • Payment Terms : L/C,T/T,

Keywords

Supply Remdesivir 1809249-37-3 Competitive price 1809249-37-3 on hot selling

Quick Details

  • Appearance:White solid powder
  • Application:Coronavirus;Covid-19
  • PackAge:25kg/drum
  • ProductionCapacity:1|Metric Ton|Month
  • Storage:Room temperature
  • Transportation:Express/Sea/Air

Superiority:

Supply Remdesivir Competitive price on hot selling

      Process Capability :   Sartort Biopharma's chemists are skilled at performing complex, multi-step syntheses and producing and sell unique chemicals around the world. 1, we are able to concentracted size and low overheads, we are able to offer prompt quotations, very competitive prices, high quality products and fast delivery. 2, All chemicals are typically >97% , For building blocks, The structure and purity is confirmed by NMR and LC-MS. Intermediates and final products are analyzed by GC, HPLC, IR, NMR, MS, elemental analysis, atom-absorpting analysis and crystallographical methods.

     Sartort Biopharma is a leading company engaging in the production of Intermediates, fine chemicals, Ionic liquids and 3D printing materials. It has such controlled subsidiaries as Sartort Pharma and Sartort Advanced Material,analytical laboratories, and an 10,000 m2 facility housing our process R&D labs, kilo lab and pilot plant, we have the skills, knowledge and experience to meet your kilo/commercial scale manufacturing needs.We would appreciate the opportunity to work with your company by providing the best quality, service, and technical support with very competitive pricing.

     Sartort Biopharma supplies large quantities of high-quality Remdesivir. First of all, in terms of price, we are at a competitive price. Because our company wants high-quality products to benefit more people and make them available to more people, we chose the pricing after comparing the market price, which is slightly lower than the market price and is market competitive.  Secondly, in terms of quality, obviously, the popularity of our products is not only because of their low prices, but at the same time our quality is guaranteed. Our internal scientific research team checks at all levels to strictly control the quality of products. Outside, we have obtained CAS certification, which is quite an authoritative recognition.

    Currently. Our high-quality Remdesivir is on hot selling, you are welcome to buy. Feel free to contact us.  

our client.jpg

     

    

    

Details:

Supply Remdesivir Competitive price on hot selling

     Remdesivir (Remdesivir) is a nucleoside analog and is an inhibitor of RNA-dependent RNA polymerase (RdRp), which can inhibit viral nucleic acid synthesis and anti-virus. The current clinical Chemicalbook bed study for Ebola virus infection is in phase II. MERS-infected mice performed much better after receiving this combination therapy, with reduced virus replication and improved lung function. Recent studies have shown that Remdesivir has a certain active effect on inhibiting the new coronavirus.

    Application status
 
    Remdesivir is a nucleotide analog prodrug. In vitro experiments and animal model data indicate that Redecive inhibits SARS (SARS coronavirus) and Middle East respiratory syndrome (MERS coronavirus) by inhibiting RNA-derived RNA polymerase (RdRp). , Chemicalbook Ebola coronavirus and many other coronaviruses. In vitro cell experiments show that the median effective concentration (IC50) of Radixivir against the new coronavirus is 0.77μmol·L-1. However, Remdesivir has not been approved for marketing in any country, and its effectiveness and safety have not been confirmed by phase III clinical trials, and only phase II clinical trials have been carried out for Ebola virus.
 
   Biological activity
    Remdesivir (GS-5734) is a nucleoside analog with antiviral activity. In HAE cells, the EC50 value of SARSChemicalbook-CoV and MERS-CoV is 74nM. In delayed brain tumor cells, it has antiviral activity. 
The EC50 value is 30 nM.
 
   Remdesivir is a nucleoside analogue being researched by Gilead Sciences. On May 7, 2020, the Japanese government approved Gilead Sciences (GILD.US) drug Remdesivir for the treatment of new crowns Viral drugs have become the country's first officially approved drug for the treatment of new coronavirus-related diseases, and priority is given to severely ill patients. 
Remdesivir has not been licensed or approved in countries other than Japan. In May 2020, Remdesivir was authorized by the U.S. Food and Drug Administration (FDA) with an emergency use authorization (EUA). Although it has not been officially approved by the FDA, its Chemicalbook has a very broad market prospect and has certain strategic drug value. Remdesivir has broad-spectrum antiviral activity. It has shown its effect on a variety of emerging viral pathogens in in vitro and in vivo studies in animal models, including Ebola virus, Marburg virus, and Middle East respiratory syndrome (MERS 
) And atypical pneumonia (SARS) viruses, so remdesivir may play a therapeutic role in epidemics caused by similar viruses in the future. At present, Remdesivir has been approved for use in various forms in 41 countries and regions including the United States, Japan, the United Kingdom, the European Union, the United Arab Emirates, India and Canada.
 
     Product advantage introduction:
     Remdesivir is a nucleoside analogue being researched by Gilead Sciences. On May 7, 2020, the Japanese government approved Gilead Sciences (GILD.US) drug Remdesivir for the treatment of new crowns Viral drugs have become the country's first officially approved drug for the treatment of new coronavirus-related diseases, and priority is given to severely ill patients. 
Remdesivir has not been licensed or approved in countries other than Japan. In May 2020, Remdesivir was authorized by the U.S. Food and Drug Administration (FDA) with an emergency use authorization (EUA). Although it has not been officially approved by the FDA, its Chemicalbook has a very broad market prospect and has certain strategic drug value. Remdesivir has broad-spectrum antiviral activity. It has shown its effect on a variety of emerging viral pathogens in in vitro and in vivo studies in animal models, including Ebola virus, Marburg virus, and Middle East respiratory syndrome (MERS 
) And atypical pneumonia (SARS) viruses, so remdesivir may play a therapeutic role in epidemics caused by similar viruses in the future. At present, Remdesivir has been approved for use in various forms in 41 countries and regions including the United States, Japan, the United Kingdom, the European Union, the United Arab Emirates, India and Canada.
Product advantage introduction:
     
 
   
Product name  Remdesivir
Cas number  1809249-37-3
Molecular formula C27H35N6O8P
Molecular weight 602.58
Appearance White solid powder
Loss on drying 0.5%
Residue in ignition ≤0.1%
Individuel impurity 0.1%
Total impurities 1.0%
Specific Rotation -19°~ -22°
Assay 98.0%~101.0%
 
 
     

Related Searches

Confirm to collect the product to my collection?

OKCancel

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View